ClinConnect ClinConnect Logo
Search / Trial NCT06410222

Predictive Models for the Treatment of Recurrent Herpes Zoster Neuralgia Following Spinal Cord Electrical Stimulation.

Launched by FENG GAO · May 9, 2024

Trial Information

Current as of July 01, 2025

Enrolling by invitation

Keywords

Herpes Zoster Post Herpes Zoster Spinal Cord Stimulation

ClinConnect Summary

Shingles is a neuropathic disease caused by varicella-herpes virus(VZV) invading nerves and accompanying pain. About 3\~5/1000 people suffer from shingles every year in the world, and 2.9\~5.8/1000 people over the age of 50 in China suffer from shingles every year, with an annual growth rate of 2.5\~5.0%. If acute herpes zoster can not be treated effectively, it will be transformed into postherpetic neuralgia (PHN), patients will suffer long-term knife, needle, burning pain as well as hyperalgesia, touch induced pain and skin paresthesia, which seriously affect the daily life of patients. I...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥18 years old.
  • NRS score ≥4 points.
  • The pain NRS of previous shingles area treated with SCS was ≤3, and the pain NRS was \> 4 after recurrence.
  • Exclusion Criteria:
  • Serious cardiovascular and cerebrovascular diseases, such as heart failure, intracranial aneurysm, hypertension (high risk, very high risk).
  • Epilepsy, suffering from mental illness.
  • And patients who were lost to follow-up.

About Feng Gao

Feng Gao is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on rigorous scientific methodologies and ethical standards, Feng Gao collaborates with healthcare professionals and research institutions to facilitate the development and testing of novel treatments across various medical fields. By prioritizing patient safety and data integrity, the organization aims to contribute significantly to the advancement of healthcare and the discovery of effective interventions for unmet medical needs.

Locations

Wuhan, Hubei, China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported